45th week of 2013 patent applcation highlights part 51 |
Patent application number | Title | Published |
20130296279 | SUBSTITUTED TETRACYCLINES - The invention in one embodiment is directed to a compound of formula (I) | 2013-11-07 |
20130296280 | EUTECTIC MIXTURE COMPRISING CELECOXIB AND POLOXAMER - The present invention relates to a eutectic mixture wherein poloxamer is added to the poorly soluble drug celecoxib to significantly increase the solubility and bioavailability of celecoxib. | 2013-11-07 |
20130296281 | Aryl Substituted Indoles and Their Use as Blockers of Sodium Channels - The invention relates to aryl and heteroaryl substituted compounds of Formula (I), and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein G, R | 2013-11-07 |
20130296282 | Methods Of Use For 2,5-Dihydroxybenzene Sulfonic Acid Compounds For The Treatment Of Cancer, Rosacea And Psoriasis - The invention describes compositions and methods of use for 2,5-dihydroxybenzene sulfonic acid compounds and pharmaceutically acceptable salts thereof. The invention provides methods for (a) treating skin cancer; (b) treating cancer of the organs; (c) treating leukemia; (d) improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy; (e) treating rosacea; and (f) treating psoriasis by administration of a composition comprising at least one 2,5-dihydroxybenzene sulfonic acid compound or a pharmaceutically acceptable salt thereof, and, optionally at least one therapeutic agent. Also disclosed are compositions comprising administration of at least one 2,5-dihydroxybenzene sulfonic acid compound, or a pharmaceutically acceptable salt thereof, and, at least one therapeutic agent. In the invention the 2,5-dihydroxybenzene sulfonic acid compounds or pharmaceutically acceptable salts thereof are 2,5-dihydroxybenzene sulfonic acid, calcium 2,5-dihydroxybenzenesulfonate, potassium 2,5-dihydroxybenzenesulfonate, magnesium 2,5-dihydroxybenzenesulfonate and diethylamine 2,5-dihydroxybenzenesulfonate. | 2013-11-07 |
20130296283 | POLYMORPHS OF DONEPEZIL SALTS, PREPARATION METHODS AND USES THEREOF - Preparation methods of mesylate, para-toluenesulfonate, succinate, tartrate, sulphate, nitrate, phosphate, salicylate, fumarate, maleate, gallate, acetylsalicylate, benzenesulphonate, citrate, aspartate, glutaminate, lactate, gluconate, ascorbate, malonate, malate, sorbate, acetate or formate of 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine (i.e., Donepezil). Novel polymorphs formed from these salts and their preparation methods. Co-crystals formed from Donepezil hydrochloride and maleic acid, fumaric acid, citric acid, salicylic acid, tartaric acid or succinic acid. | 2013-11-07 |
20130296284 | MICROEMULSION & SUB-MICRON EMULSION PROCESS & COMPOSITIONS - An oil in water microemulsion or sub-micron emulsion composition for dermal delivery of at least one pharmaceutically active ingredient, is provided. The composition includes an oil phase dispersed throughout a water phase, the oil phase including at least one member selected from the group consisting of an animal oil, a mineral oil, a vegetable oil, a silane member, a siloxane, an ester, a fatty acid, a fat, a halogen compound, and an alkoxylated alcohol; and at least one lipophilic surfactant, the water phase including at least one hydrophilic surfactant, water and optionally a non-surfactant amphiphilic compound, the weight ratio of the at least one hydrophilic surfactant to the at least one lipophilic surfactant being approximately 9.0:1.0 to 2.0:3.0. | 2013-11-07 |
20130296285 | Design of Hydrolytically Releasable Prodrugs for Sustained Release Nanoparticle Formulations - A prodrug according to formula (I) wherein R | 2013-11-07 |
20130296286 | VISCOUS BUDESONIDE FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE GASTROINTESTINAL TRACT - Provided herein are methods for preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention. | 2013-11-07 |
20130296287 | FOCAL PHOTODYNAMIC THERAPY METHODS - Improved methods of treating prostate cancer by vascular-targeted photodynamic therapy, and improved methods of planning treatment, are presented using a light density index to plan and guide effective treatment. | 2013-11-07 |
20130296288 | ORGANIC ELECTROLUMINESCENT DEVICE - The present invention relates to a salt in which at least one cation and at least one anion is in each case an emitter compound or a dye compound, characterised in that at least one of the emitter compounds is a fluorescent emitter compound. In addition, the present invention also relates to a process for the preparation of the salt according to the invention, to the use of the salt in an electronic device, and to a formulation and an electronic device which comprises the salt. | 2013-11-07 |
20130296289 | ANTI-DANDRUFF SHAMPOO - The invention relates to an anti-dandruff shampoo comprising: —a) from 0.1 to 5 wt. % of an anti-dandruff zinc salt; b) from 1 to 8 wt. % of a branched alkyloyi isethionate; c) from 1 to 10 wt. % of a fatty acyl isethionate product which product comprises 40 to 80 wt. % fatty acyl isethionate and 15 to 50 wt. % free fatty acid and/or fatty acid salt; and, d) from 0.5 to 14 wt. % of a co-surfactant; and to the use of the branched alkyloyi isethionate to improve the deposition of an anti-dandruff zinc salt onto the scalp. | 2013-11-07 |
20130296290 | 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS - β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D β-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed. | 2013-11-07 |
20130296291 | 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS - β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D β-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed. | 2013-11-07 |
20130296292 | 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS - β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D β-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed. | 2013-11-07 |
20130296293 | 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS - β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D β-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed. | 2013-11-07 |
20130296294 | TREATMENT AND/OR PREVENTION OF PARKINSON'S DISEASE DEMENTIA WITH CEFTRIAXONE - Disclosed herein is a method for treatment of a human subject having or suspected of having Parkinson's disease dementia, which includes administering to the human subject ceftriaxone at a daily dosage ranging from about 1.5 mg to about 35 mg per kilogram of a body weight of the human subject. | 2013-11-07 |
20130296295 | BCL-2 SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES - Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein. | 2013-11-07 |
20130296296 | 2-Carboxamide-7-Piperazinyl-Benzofuran Derivatives - The present invention relates to compounds of formula (I), | 2013-11-07 |
20130296297 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS - Disclosed are compounds, compositions and methods for treating diseases, syndromes, conditions and disorders that are affected by the inhibition of MGL, including pain. Such compounds are represented by Formula (I) as follows: | 2013-11-07 |
20130296298 | TRIAZOLOPYRIDAZINE COMPOUNDS, USE AS INHIBITORS OF THE KINASE LRRK2, AND METHODS FOR PREPARATION THEREOF - The present invention provides novel LRRK2 kinase inhibitors and methods of treating disease states using these inhibitors. | 2013-11-07 |
20130296299 | PYRROLO[2,3-b]PYRIDIN-4-YL-AMINES AND PYRROLO[2,3-b]PYRIMIDIN-5-YL-AMINES AS JANUS KINASE INHIBITORS - The present invention provides pyrrolo[2,3-b]pyridine-4-yl amines pyrrolo[2,3-b]pyrimidin-4-yl amines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases and cancer. | 2013-11-07 |
20130296300 | QUINOLINES AND AZA-QUINOLINES AS CRTH2 RECEPTOR MODULATORS - The invention provides certain quinolines and aza-quinolines of the Formula (I), and their pharmaceutically acceptable salts, wherein E, J | 2013-11-07 |
20130296301 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF - The invention is directed to compounds for selectively inhibiting glycosidases, uses of the compounds and pharmaceutical compositions including the compounds, and methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, and/or accumulation or deficiency of O-GlcNAc. | 2013-11-07 |
20130296302 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF - Provided herein are compounds according to Formulas (I) or (II) and pharmaceutically acceptable salts thereof, and compositions comprising the same, for use in various methods, including treating cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, osteoarthritis, idiopathic pulmonary fibrosis and neurological conditions/disorders/diseases. | 2013-11-07 |
20130296303 | SPIRO-OXINDOLE MDM2 ANTAGONISTS - Provided herein are compounds, compositions, and methods in the field of medicinal chemistry. The compounds and compositions provided herein relate to spiro-oxindoles which function as antagonists of the interaction between p53 and MDM2, and their use as therapeutics for the treatment of cancer and other diseases. | 2013-11-07 |
20130296304 | TRICYCLIC FUSED RING INHIBITORS OF HEPATITIS C - Provided herein are compounds, pharmaceutical compositions and combination therapies for treatment of hepatitis C. | 2013-11-07 |
20130296305 | TRICYCLIC PYRROLO DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS - The present invention relates to tricyclic pyrrolo derivatives of Formula (I), which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing such these compounds or the pharmaceutical compositions containing them. | 2013-11-07 |
20130296306 | Modulators of ATP-Binding Cassette Transporters - Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention. | 2013-11-07 |
20130296307 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF - Provided herein are compounds according to Formula I and pharmaceutically acceptable salts thereof, and compositions comprising the same, for use in various methods, including treating cancers such as colon, ovarian, pancreatic, breast, liver, prostate and hematologic cancers: | 2013-11-07 |
20130296308 | Heterocyclic Substituted Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds - Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I, | 2013-11-07 |
20130296309 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS - The present invention provides a compound of formula I; | 2013-11-07 |
20130296310 | THIAZOLE AND OXAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS - Compounds of the formula I: | 2013-11-07 |
20130296311 | INHIBITORS OF HCV NS5A - Provided herein are compounds, pharmaceutical compositions and combination therapies for inhibition of hepatitis C. | 2013-11-07 |
20130296312 | Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives - This application relates, in part, to compounds of the general Formula I | 2013-11-07 |
20130296313 | PLANT DISEASE CONTROL AGENT - The present invention provides a plant disease control agent containing at least one of tetrazoyloxime dirvatives and salts thereof, and at least one selected from the group consisting of fosetyl, propamocarb, basic copper chloride, chlorothalonil, manzeb, cymoxanil, folpet, iminoctadine, cyazofamid, metalaxyl, fludioxonil, tebuconazole, prothioconazole, thiamethoxam, azoxystrobin and salts thereof. | 2013-11-07 |
20130296314 | GASTRIC AND COLONIC FORMULATIONS AND METHODS FOR MAKING AND USING THEM - In alternative embodiments, the invention provides compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments or lavage, e.g., orthostatic lavage, e.g., for inducing the purgation (e.g., cleansing) of a gastrointestinal (GI) tract, including a colon; and methods for making and using them. In alternative embodiments, compositions and methods of the invention are used for the amelioration, treatment and/or prevention of constipation, for the treatment of abdominal pain, particularly non-specific abdominal pain, and diarrhea, including diarrhea caused by a drug side effect, a psychological condition, a disease or a condition such as Crohn's Disease, a poison, a toxin or an infection, e.g., a toxin-mediated traveler's diarrhea. In alternative embodiments, the invention provides pharmaceuticals and products (articles) of manufacture for delivering these compositions and formulations to an individual, e.g., a human or an animal. | 2013-11-07 |
20130296315 | Use of Dithiine Derivatives in Crop Protection and the Protection of Materials - The present invention relates to the use of new and known dithiine derivatives for controlling unwanted microorganisms, more particularly phytopathogenic fungi, in crop protection, in the household and hygiene sector and in the protection of materials, and also to new dithiine derivatives, to processes for preparing them, to their use, and to crop protection compositions comprising these new dithiine derivatives. | 2013-11-07 |
20130296316 | Antiparasitic Agents Based On mTOR Inhibitors - Disclosed is the use of mammalian target of rapamycin (mTOR) and/or phosphoinositide-3-kinase (PI3K) inhibitors as antiparasitic drugs, particularly in those parasitic infections caused by trypanosomatid parasites { | 2013-11-07 |
20130296317 | LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY - Disclosed are compounds of Formula (I): and the pharmaceutically acceptable salts thereof, wherein “A” is S—; —SO—, —SO | 2013-11-07 |
20130296318 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS - The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf. | 2013-11-07 |
20130296319 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS - The invention provides a compound of Formula (I) | 2013-11-07 |
20130296320 | NOVEL BICYCLIC COMPOUND OR SALT THEREOF - Provided is a novel bicyclic compound which has an HSP90 inhibitory effect and a carcinostatic effect. Also provided is a pharmaceutical agent which is based on the HSP90 inhibitory effect and is useful in the prevention and/or treatment of a disease involving HSP90, particularly, cancer. The present invention provides a compound represented by the following general formula (I) or a salt thereof wherein at least one of X | 2013-11-07 |
20130296321 | CRYSTALLINE FORMS AND PROCESSES FOR THE PREPARATION OF PHENYL-PYRAZOLES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR - The present invention relates to processes for preparing phenyl-pyrazoles of Formula (I) and salts and pharmaceutical compositions thereof, useful as modulators of 5-HT | 2013-11-07 |
20130296322 | SEROTONIN REUPTAKE INHIBITORS - In one aspect, the invention relates to compounds of formula I: | 2013-11-07 |
20130296323 | GGA AND GGA DERIVATIVES COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM - This invention relates to geranylgeranyl acetone (GGA) derivatives and the use of GGA, its isomers, and GGA derivatives in methods for inhibiting neural death, increasing neural activity, increasing axon growth and cell viability, and increasing the survival rate of subjects administered the GGA or GGA derivatives. | 2013-11-07 |
20130296324 | NOVEL COMPOSITIONS COMPRISING A PHOSPHODIESTERASE-5 INHIBITOR AND THEIR USE IN METHODS OF TREATMENT - The invention relates generally to novel pharmaceutical methods for the treatment of various conditions. Compositions comprising: at least one phosphodiesterase-5-inhibitor in combination with one or more of the following medications: a selective serotonin reuptake inhibitor; a serotonin-norepinephrine reuptake inhibitor; a cholinesterase inhibitor; a dopamine agonist; or a medication suitable to increase the chemical concentrations of the neurotransmitters, selected from amino acids, monoamines, neuropeptides and other agents capable of primary neurotransmission in the synaptic clefts, and their use for treating a neurodegenerative disease in a subject. The invention also relates to: Compositions comprising: at least one phosphodiesterase-5-inhibitor in combination with one or more of the following medications: a selective serotonin reuptake inhibitor; or a cholinesterase inhibitor, and their use for treating damaged skin in a subject. | 2013-11-07 |
20130296325 | HIGH DRUG LOAD TABLET FORMULATION OF [(1R), 2S]-2-AMINOPROPIONIC ACID 2-[4-(4-FLUORO-2-METHYL-1H-INDOL-5-YLOXY)-5-METHYLPYRROLO[2,1-f][1,2,4]TR- IAZIN-6-YLOXY]-1-METHYLETHYL ESTER - The present invention is directed to a high drug load tablet formulation of [(1R),2S]-2-aminopropionic acid 2-[4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]-1-methylethyl ester, and to methods of using the formulation in the treatment of cancer. The tablet is obtained by means of a wet granulation process. | 2013-11-07 |
20130296326 | SUSCEPTIBILITY OF TUMORS TO TYROSINE KINASE INHIBITORS AND TREATMENT THEREOF - This disclosure provides tyrosine kinase protein and nucleic acid variants, particularly FGFR2 variants, which are linked to drug resistance. The disclosure further provides methods of diagnosis and theranosis, using these molecules and fragments thereof, and kits for employing these methods and compositions. | 2013-11-07 |
20130296327 | SUBSTITUTED HETEROCYLIC COMPOUNDS - The present invention relates to substituted heterocyclic compounds of Formula I or XI: | 2013-11-07 |
20130296328 | EPIGENETIC PORTRAITS OF HUMAN BREAST CANCERS - The present invention provides new target gene regions for use in prediction, prognosis, diagnosis and therapy of breast cancer, based on the differential methylation profile of said targets in samples from subjects with breast cancer and healthy subjects. | 2013-11-07 |
20130296329 | QUINOXALINE COMPOUND - The present inventors have investigated a compound which has a PDE9-inhibitory action and is useful as an active ingredient for an agent for treating and/or preventing storage dysfunction, voiding dysfunction, and bladder/urethral diseases, and the like, and thus, have found that an imidazoquinoxaline compound or a triazoloquinoxaline compound has a PDE9-inhibitory action, thereby completing the present invention. | 2013-11-07 |
20130296330 | MACROCYCLIC INTEGRASE INHIBITORS FOR USE IN THE TREATMENT OF FELINE IMMUNODEFICIENCY VIRUS - This invention concerns to naphthyridin derivatives of formula (I) for use in the treatment or prevention of feline immunodeficiency virus (FIV). Furthermore the present invention relates to a method of treating or preventing infection of feline immunodeficiency virus in a feline animal wherein said method comprises the administration to said feline animal of a therapeutically effective amount of a naphthyridin derivative. | 2013-11-07 |
20130296331 | COMPOSITIONS AND METHODS FOR AMELIORATING RENAL DYSFUNCTION INDUCED BY RENAL HYPOPERFUSION OR ACUTE KIDNEY INJURY - The invention provides compositions and methods for ameliorating renal dysfunction induced by renal hypoperfusion or acute kidney injury, resulting for example from increased intra-abdominal pressure, using phosphodiesterase inhibitors, more particularly phosphodiesterase type inhibitors, or pharmaceutically acceptable salts or solvates thereof. | 2013-11-07 |
20130296332 | 1H-QUINAZOLINE-2,4-DIONES - The present invention relates to 1H-Quinazoline-2,4-diones of formula (I) | 2013-11-07 |
20130296333 | HEDGEHOG PATHWAY MODULATORS - The invention provides a method, compounds and compositions for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or Gli gain-of-function, comprising contacting a cell with a sufficient amount of a compound of Formula (I). | 2013-11-07 |
20130296334 | ORGANIC AMINE SALTS OF AZILSARTAN, PREPARATION METHOD AND USE THEREOF - Disclosed are organic amine salts of azilsartan, a preparation method and use thereof. In particular, disclosed are organic amine salts of azilsartan, their preparation method, the pharmaceutical composition comprising the compound in a therapeutically effective quantity, and their use for the manufacture of antihypertensive medicaments. | 2013-11-07 |
20130296335 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS - Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure. | 2013-11-07 |
20130296336 | 5-HT1A RECEPTOR SUBTYPE AGONIST - The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT | 2013-11-07 |
20130296337 | FLASHMELT ORAL DOSAGE FORMULATION - There is provided granules for the production of flash-melt pharmaceutical oral dosage forms. In addition to one or more medicaments, the granules are composed of an excipient combination consisting of a superdisintegrant, a dispersing agent, a distributing agent, and a binder and may also include other conventional ingredients such as sweetening and flavoring agents. The subject granules are advantageous in that they are stable and can be prepared without the aid of solvents and without the need for special environments or handling. Dosage forms, especially tablets, prepared therefrom on conventional equipment disintegrate in the mouth in under about twenty five seconds. | 2013-11-07 |
20130296338 | Quinoline and Quinoxaline Derivatives as Kinase Inhibitors - A series of quinoline and quinoxaline derivatives comprising a fluorinated ethyl side-chain, being selective inhibitors of P13 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions. | 2013-11-07 |
20130296339 | ISOINDOLINONE DERIVATIVES - The present invention relates to compounds of the formula I, | 2013-11-07 |
20130296340 | PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES - A pyridone derivative compound and a pharmaceutically acceptable salt, isomer, solvate or hydrate thereof, and a preventive or therapeutic pharmaceutical composition for cognitive disorders that includes the pyridone derivative compound or a pharmaceutically acceptable salt, isomer, solvate or hydrate thereof. | 2013-11-07 |
20130296341 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF - Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases due to mutations in Wnt signaling components. Also provided are methods for treating Wnt-related disease states. | 2013-11-07 |
20130296342 | LIPOPROTEIN LIPASE-ACTIVATING COMPOSITIONS COMPRISING BENZENE DERIVATES - The present invention provides pharmaceutical compositions containing benzene compound(s) represented by General Formula (1) below and, particularly, LPL-activating compositions for use in hyperlipidemia therapeutic and preventive agents, anti-obesity agents, and the like: | 2013-11-07 |
20130296343 | SUBSTITUTED IMIDAZO- AND TRIAZOLOPYRIMIDINES, IMIDAZO- AND PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES - The invention relates to substituted imidazo- and triazolopyrimidines, imidazo- and pyrazolopyrazines and imidazotriazines and processes for their preparation, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, in particular of hematological disorders, preferably of leukopenias and neutropenias. | 2013-11-07 |
20130296344 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS - Compounds according to the general formula (I) wherein X | 2013-11-07 |
20130296345 | METHODS FOR TREATING HYPERURICEMIA AND RELATED DISEASES - Provided herein are methods of treating gout, treating hyperuricemia, lowering serum uric acid, or the like with compounds of formula (I) have the following structure Further, provided herein are compositions comprising a compound of formula (I). | 2013-11-07 |
20130296346 | DIPHENYL-AMINE DERIVATIVES: USES, PROCESS OF SYNTHESIS AND PHARMACEUTICAL COMPOSITIONS - The invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, prodrug or solvate thereof, a method of synthesis of said compounds, pharmaceutical compositions comprising them and their use as a medicament for treating inflammatory diseases. | 2013-11-07 |
20130296348 | Bis-Quinazoline Derivatives as Inhibitors for Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase - Novel bis-quinazoline derivatives as tyrosine kinase inhibitors, synthesis of these compounds, and novel methods for treating tyrosine kinase mediated diseases or disorders using these compounds are disclosed. In particular, the present invention provides tethered quinazoline derivative dimers as inhibitors to the epidermal growth factor receptor (EGFR) tyrosine kinase, pharmaceutical compositions thereof, and their therapeutic uses for treating EGFR kinase-mediated diseases or disorders, such as various cancers, as well as synthetic methods for preparing these novel compounds. | 2013-11-07 |
20130296349 | QUINAZOLINONE INHIBITORS OF DYNEIN - Compounds of formula (I) in which R | 2013-11-07 |
20130296350 | Method of Treatment or Prophylaxis - The present invention is directed to methods and agents that are useful in the prevention and amelioration of signs and symptoms associated with neuropathic conditions. More particularly, the present invention discloses the use of angiotensin II receptor 2 (AT | 2013-11-07 |
20130296351 | 2-Thiopyrimidinones - Myeloperoxidase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, cardiovascular conditions. | 2013-11-07 |
20130296352 | PYRAZOLOQUINOLINE DERIVATIVES - A compound and/or pharmacologically acceptable salt thereof represented by the formula (I) has PDE9 inhibitory action, so that the intracerebral cGMP concentration is anticipated to be elevated. The PDE9 inhibitory action and the increase in cGMP lead to the improvement of learning and memory behaviors, and the compound (I) has applicability as a therapeutic agent for cognitive dysfunctions in Alzheimer's disease. | 2013-11-07 |
20130296353 | CRYSTALLINE PHARMACEUTICALLY ACTIVE INGREDIENTS - The present invention is related to crystalline forms of rosuvastatin zinc (2:1) salt. The polymorphs are suitable for use as pharmaceutically active ingredients in the treatment of the diseases of the lipid metabolism including hypercholesterolemia, hyperlipidemia, dyslipidemia or atherosclerosis. | 2013-11-07 |
20130296354 | 2,3-DIHYDROFURO[2,3-c]PYRIDINES, THEIR USE AS MODULATORS OF THE G-PROTEIN-COUPLED RECEPTOR GPR119 AND PHARMACEUTICAL COMPOSITIONS THEREOF - The present invention relates to compounds of general formula I, | 2013-11-07 |
20130296355 | GLUCAGON RECEPTOR MODULATORS - The present invention provides a compound of Formula (I) | 2013-11-07 |
20130296356 | COMBINATIONS - The present invention relates to a method of treating ovarian cancer in a female human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a ovarian cancer treatment method that includes administering 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide, or a pharmaceutically acceptable salt thereof, and 2-[(5-chloro-2-[[3-methyl-1-(1-methylethyl)-1H-pyrazol-5-yl]amino]-4-pyridinyl)amino]-N-methoxybenzamide, or a pharmaceutically acceptable salt thereof, and optionally 1,7β,10β-trihydroxy-9-oxo-5β,20-epoxytax-11-ene-2α,4,13α-triyl 4-acetate 2-benzoate 13-{(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoate}, to a human in need thereof. | 2013-11-07 |
20130296357 | METHODS OF USING ALK INHIBITORS - The invention provides methods for using compounds of Formula (I) for treating an EML4-ALK | 2013-11-07 |
20130296358 | 3-SPIROCYCLIC PIPERIDINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS - The invention relates to derivatives of formula (I), | 2013-11-07 |
20130296359 | TREATMENT OF SOLID TUMORS WITH RAPAMYCIN DERIVATIVES - The present invention is directed to the use of rapamycin derivatives for use in treating solid tumors, optionally in combination with a chemotherapeutic agent. | 2013-11-07 |
20130296360 | BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2 - The present invention relates to new benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), pharmaceutical compositions thereof, and methods of use thereof. | 2013-11-07 |
20130296361 | Condensed Ring Pyridine Compounds As Subtype-Selective Modulators Of Sphingosine-1-Phosphate-2 (S1P2) Receptors - The invention provides compounds represented by the formula I, each of which compounds may have sphingosine-1-phosphate receptor agonist and or antagonist biological activity, wherein these compounds selected from the group consisting of | 2013-11-07 |
20130296362 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS - The present invention is related to pyrazolo pyridine derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase). | 2013-11-07 |
20130296363 | QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR USE AS JAK MODULATORS - Provided herein are compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions. | 2013-11-07 |
20130296364 | MODULATORS OF ATP-BINDING CASSETTE-TRANSPORTERS - Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention. | 2013-11-07 |
20130296365 | QUINOLINE DERIVATIVE-CONTAINING PHARMACEUTICAL COMPOSITION - A pharmaceutical composition comprising a compound represented by the formula (I) or pharmaceutically acceptable salt thereof or solvate thereof, and a basic substance is excellent in dissolution, is stable even after a long term storage, and is useful as a preventive or therapeutic agent against a tumor: | 2013-11-07 |
20130296366 | OPTICAL ISOMERS OF AN ILOPERIDONE METABOLITE - The present invention relates to novel isomers of a metabolite of Iloperidone, their preparation, their use as pharmaceuticals and pharmaceutical compositions containing them. | 2013-11-07 |
20130296367 | COMPOSITIONS AND METHODS FOR ALLEVIATING DEPRESSION OR IMPROVING COGNITION - This application describes compositions of receptor inhibitors, including antipsychotic agents, for example haloperidol, and methods of use for alleviating clinical depression, improving cognition and/or treating other syndromes, conditions or diseases for which anti-depressant agents are prescribed. Furthermore, this application describes compositions and methods to induce supersensitivity in dopamine D2 and other receptors involved in depression and/or cognition as a means of alleviating clinical depression or improving cognition. | 2013-11-07 |
20130296368 | SUBLINGUAL FENTANYL SPRAY - The present invention is directed to sublingual formulations containing fentanyl, a pharmaceutically acceptable sale thereof, or derivative thereof, suitable for administration to a patient, and methods for treatment with the formulations. | 2013-11-07 |
20130296369 | Cyanoenamines and their use as fungicides - The present invention relates to cyanoenamine derivatives, their process of preparation, intermediate compounds, their use as fungicide active agents, particularly in the form of fungicide compositions, and methods for the control of phytopathogenic fungi, notably of plants and in material protection, using these compounds or compositions. | 2013-11-07 |
20130296370 | COMPOSITION COMPRISING A PHOTOACTIVATABLE LARVICIDE - A composition comprising a photoactivatable larvicide and a suitable vector, the latter allowing the larvicide to be ingested by the larvae and a method for controlling mosquito larvae by using said photoactivatable larvicide are disclosed. | 2013-11-07 |
20130296371 | MACROCYCLIC PICOLINAMIDES AS FUNGICIDES - The disclosure relates to macrocyclic picolinamides of Formula I and their use as fungicides. | 2013-11-07 |
20130296372 | USE OF PRO-FUNGICIDES OF UK-2A FOR CONTROL OF SOYBEAN RUST - The present disclosure is related to the field of agrochemicals, including profungicides of UK-2A and their use to control soybean rust. | 2013-11-07 |
20130296373 | MACROCYCLIC PICOLINAMIDES AS FUNGICIDES - The disclosure relates to macrocyclic picolinamides of Formula I and their use as fungicides. | 2013-11-07 |
20130296374 | USE OF PRO-FUNGICIDES OF UK-2A FOR CONTROL OF BLACK SIGATOKA - The present disclosure is related to the field of agrochemicals, including profungicides of UK-2A and their use to control Black Sigatoka. | 2013-11-07 |
20130296375 | MACROCYCLIC PICOLINAMIDES AS FUNGICIDES - The invention relates to macrocyclic picolinamides of Formula I and their use as fungicides. | 2013-11-07 |
20130296376 | ONE POT PROCESS FOR THE PREPARATION OF BENZIMIDAZOLE DERIVATIVES - The present invention discloses one pot process for enantioselective synthesis of single enantiomers of substituted sulphoxides 2-(2-pyridinylmethylsulphinyl)-1H-benzimidazoles or said compounds in an enantiomerically enriched form. | 2013-11-07 |
20130296377 | Complement pathway modulators and uses thereof - The present invention provides a compound of formula I: | 2013-11-07 |
20130296378 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY - The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound. | 2013-11-07 |
20130296379 | Solid Forms of 3-(6-(1-(2,2-Difluorobenzo[D][1,3]Dioxol-5-yl)Cyclopropanecarboxamido)-3-- Methylpyridin-2-yl)Benzoic Acid - The present invention relates to a substantially a solid form of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound 1, Solvate Form A and Compound 1, HCl Salt Form A), processes for making such forms, pharmaceutical compositions thereof, and methods of treatment therewith. | 2013-11-07 |